Why NovoCure Stock Dived by 13% This Week

Investors found the announced changes to the company's C-suite unsettling. A series of C-suite changes negatively affected the share price of cancer-focused biotech NovoCure (NVCR -6.48%) across the holiday-shortened trading week. When the smoke cleared, the company's stock had eroded by slightly over 13% over the Tuesday to Friday stretch, according to data compiled by S&P Global Market Intelligence. Major changes in top management On Tuesday, NovoCure announced that long-serving CEO Asaf Danziger is stepp ...